In the past week, BMRN stock has gone down by -0.88%, with a monthly decline of -0.54% and a quarterly plunge of -17.10%. The volatility ratio for the week is 1.77%, and the volatility levels for the last 30 days are 1.71% for Biomarin Pharmaceutical Inc.. The simple moving average for the past 20 days is 0.13% for BMRN’s stock, with a -16.04% simple moving average for the past 200 days.
Is It Worth Investing in Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) Right Now?
Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) has a price-to-earnings ratio of 52.78x that is above its average ratio. Additionally, the 36-month beta value for BMRN is 0.30. There are mixed opinions on the stock, with 12 analysts rating it as a “buy,” 7 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BMRN is 187.97M and currently, short sellers hold a 2.98% ratio of that float. The average trading volume of BMRN on October 30, 2024 was 1.73M shares.
BMRN) stock’s latest price update
Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) has experienced a decline in its stock price by -0.31 compared to its previous closing price of 70.13. However, the company has seen a fall of -0.88% in its stock price over the last five trading days. seekingalpha.com reported 2024-10-29 that BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Traci McCarty – Head of Investor Relations Alexander Hardy – President and Chief Executive Officer Brian Mueller – Executive Vice President and Chief Financial Officer Cristin Hubbard – Executive Vice President and Chief Commercial Officer Greg Friberg – Executive Vice President and Chief Research & Development Officer Conference Call Participants Philip Nadeau – TD Cowen Salveen Richter – Goldman Sachs Jessica Fye – JPMorgan Paul Matteis – Stifel Eli Merle – UBS Cory Kasimov – Evercore Kostas Biliouris – BMO Capital Markets Joseph Schwartz – Leerink Partners Akash Tewari – Jefferies Christopher Raymond – Piper Sandler Mohit Bansal – Wells Fargo John Wang – Barclays Operator Thank you for standing by. My name is Bailey and I will be your conference operator today.
Analysts’ Opinion of BMRN
Many brokerage firms have already submitted their reports for BMRN stocks, with Raymond James repeating the rating for BMRN by listing it as a “Outperform.” The predicted price for BMRN in the upcoming period, according to Raymond James is $79 based on the research report published on October 10, 2024 of the current year 2024.
Bernstein, on the other hand, stated in their research note that they expect to see BMRN reach a price target of $110, previously predicting the price at $94. The rating they have provided for BMRN stocks is “Outperform” according to the report published on August 20th, 2024.
Robert W. Baird gave a rating of “Neutral” to BMRN, setting the target price at $72 in the report published on May 17th of the current year.
BMRN Trading at -8.79% from the 50-Day Moving Average
After a stumble in the market that brought BMRN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.78% of loss for the given period.
Volatility was left at 1.71%, however, over the last 30 days, the volatility rate increased by 1.77%, as shares sank -0.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.63% lower at present.
During the last 5 trading sessions, BMRN fell by -0.88%, which changed the moving average for the period of 200-days by -25.09% in comparison to the 20-day moving average, which settled at $69.82. In addition, Biomarin Pharmaceutical Inc. saw -27.49% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMRN starting from Burkhart Erin, who sale 714 shares at the price of $90.00 back on Aug 13 ’24. After this action, Burkhart Erin now owns 14,449 shares of Biomarin Pharmaceutical Inc., valued at $64,260 using the latest closing price.
Burkhart Erin, the Officer of Biomarin Pharmaceutical Inc., proposed sale 714 shares at $90.00 during a trade that took place back on Aug 13 ’24, which means that Burkhart Erin is holding shares at $64,260 based on the most recent closing price.
Stock Fundamentals for BMRN
Current profitability levels for the company are sitting at:
- 0.09 for the present operating margin
- 0.78 for the gross margin
The net margin for Biomarin Pharmaceutical Inc. stands at 0.1. The total capital return value is set at 0.04. Equity return is now at value 5.10, with 3.76 for asset returns.
Based on Biomarin Pharmaceutical Inc. (BMRN), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at 0.3. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is 13.08.
Currently, EBITDA for the company is 261.98 million with net debt to EBITDA at 0.39. When we switch over and look at the enterprise to sales, we see a ratio of 5.19. The receivables turnover for the company is 3.75for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.05.
Conclusion
In conclusion, Biomarin Pharmaceutical Inc. (BMRN) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
